Dupilumab as promising treatment for prurigo nodularis: current evidences.

Abstract

Prurigo nodularis (PN) is a debilitating chronic disease characterized by intense itching and excoriated hyperkeratotic nodules distributed on the trunk and extremities, especially the extensor surfaces. The pathophysiology includes complex and not yet well-understood mechanisms involving inflammation and dysregulation of the nervous system. Currently, there are no approved therapies by the Food and Drug Administration (FDA) and the few treatment approaches for this condition are often ineffective and related to severe side effects. An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-Rα) and the signaling pathways activated by interleukin (IL)-4 and IL-13. These cytokines seem to be involved in the development and perpetuation of PN and other type-2 inflammation diseases. Data on this topic are limited, but the emergent positive effects of this drug, reported in the literature and summarized in this review, suggest that it can be a safe and efficient therapy in PN.

• Authors: Ludovica Toffoli, Eleonora Farinazzo, Enrico Zelin, Marina Agozzino, Caterina Dianzani, Nicola Di Meo, Katiuscia Nan, Iris Zalaudek, Claudio Conforti
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 33 Issue 3 Pg. 1306-1311 (May 2022) ISSN: 1471-1753 [Electronic] England
• PMID: 33588666 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• dupilumab

Topics

• Adolescent
• Adult
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Humans
• Inflammation (drug therapy)
• Neurodermatitis
• Prurigo (drug therapy)